Top German Pharma Firm Buys Israeli Wearable Drug Dispenser

A top German pharmaceutical company has completed the purchase of an Israeli startup’s “wearable injectors,” small medical devices that are secured to a patient’s body and automatically deliver a set dose of a drug. 

Eitan Medical sold the “Sorrel” branch of its company, which makes prefilled wearable injectors that let patients living with chronic conditions self-administer medication safely and efficiently without interrupting their daily lives. 

German-based company LTS, which develops and manufactures drug delivery systems that are sold worldwide, says it has acquired the Israeli business in order to benefit from Eitan’s expertise and resources in wearable injector technology. 

“The acquisition of the Sorrel platform catapults LTS into the world of drug delivery for large molecules, and fulfills our mission to bring empowering solutions to patients that rely on cumbersome and expensive therapies requiring in-clinic administration or multiple injections,” said LTS CEO Bas van Buijtenen.

Shaul Eitan, the incoming CEO of Eitan Medical, said that the sale was part of the company’s move to focus on its infusion therapy (intravenous medication) products. 

“The decision to divest the wearable injectors business aligns with Eitan Medical’s strategic focus on its core infusion therapy portfolio, streamlining its operations, concentrating resources, and further strengthening its position as a leader in advanced and connected infusion therapy solutions,” he said.